文献速递核素与放射性配体治疗肿瘤 PET/CT

PSMA放射性配体治疗早期PSA变化可预测治疗反应与生存

Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-23

该回顾性研究纳入76例mCRPC患者,评估[177Lu]Lu-PSMA-617首周期后两天内PSA相对变化与长期生化反应及生存的关系。结果显示PSA下降或稳定者较PSA升高者更易达PCWG3部分缓解且平均生存更长。

要点

  • 首周期后2天PSA下降或稳定者PCWG3部分缓解率更高
  • PSA升高者平均生存225天,低于下降组399天和稳定组405天
  • dPSA与前两周期相对Nadir呈显著Pearson相关

核心结论

  • 首周期[177Lu]Lu-PSMA-617后2天PSA下降或稳定者较PSA升高者更可能获得PCWG3生化反应且总生存更长。

研究设计与样本

  • 回顾性研究纳入76例转移性去势抵抗性前列腺癌患者,评估首次[177Lu]Lu-PSMA-617治疗前PSA及2天后相对变化(dPSA)。

主要发现

  • 2天后32例(42%)PSA下降,其中19例(59%)按PCWG3达部分缓解;37例PSA稳定中17例(46%)部分缓解;7例PSA升高中3例(43%)部分缓解。
  • 第2天dPSA与前两周期相对Nadir呈统计学显著Pearson相关。
  • PSA下降、稳定和升高组平均生存分别为399天、405天和225天。

关键数值与推荐

  • dPSA<-10%定义为相关PSA下降,-10%≤dPSA≤+10%为稳定,dPSA>10%为相关升高。
  • 生化治疗结局按前列腺癌工作组(PCWG3)标准评估。

临床怎么用

  • 首周期[177Lu]Lu-PSMA-617后2天PSA变化或可辅助早期识别可能获益于治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We investigated whether prompt changes in prostate-specific-antigen (PSA) levels within two days after the first cycle of prostate-specific-membrane-antigen radioligand therapy (PSMA-RLT) with [177Lu]Lu-PSMA-617 predicted treatment response and mean survival. METHODS: In a retrospective study of 76 metastatic castration resistant prostate cancer (mCRPC) patients, we evaluated pretreatment PSA-values and their relative changes in PSA (dPSA) two days later. We tested for correlations between dPSA with long-term biochemical response (BCR) to treatment, using a priori criteria for relevant PSA decrease (dPSA < -10%), stable PSA (-10% ≤ dPSA ≤ + 10%) and relevant PSA increase (dPSA > 10%), along with evaluation of biochemical therapy outcome according to the Prostate-Cancer-Working-Group (PCWG3). RESULTS: Two days after the first [177Lu]Lu-PSMA-617 cycle, 32 (42%) of the patientsshowed PSA decrease, of whom 19 (59%) had experienced a partial response according toPCWG3 criteria. Of the 37 patients with stable PSA, 17 (46%) showed partial response totreatment according to PCWG3 criteria. Among the seven patients with PSA increase, three(43%) showed partial response. Pearson correlation analysis showed statistically significantcorrelations between dPSA on day 2 and relative Nadir for the first two treatment cycles.Patients with PSA decrease or stable PSA compared to those with an increase of PSA two daysafter cycle 1 lived longer on average (399, 405 and 225 days, respectively). CONCLUSION: Compared to those with increased PSA levels, patients with decreased or stable PSA levels two days after the first [177Lu]Lu-PSMA-617 RLT cycle were more likely to have favorable biochemical response according to PCWG3 criteria and presented with a longer overall survival.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bosbach WA, Alsheikh RS, Gözlügöl N, et al. Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41575546. doi:10.1007/s00259-026-07772-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。